Chylous Ascites as a Possible Rare Side Effect of Selpercatinib in RET-Positive NSCLC

We attentively read the study by Kalchiem-Dekel et al. 1 Kalchiem-Dekel O. Falcon C.J. Bestvina C.M. et al. Brief report: chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy. J Thorac Oncol. 2022; 17: 1130-1136 Abstract Full Text Full Text PDF PubMed Scopus (12) Google Scholar retrospectively reporting that chylous effusion could emerge as a potential side effect of selected RET inhibitors, especially selpercatinib. Response to Provenzano et al. and De Carlo et al.Journal of Thoracic OncologyVol. 18Issue 2PreviewWe appreciate the comments from Provenzano et al. and De Carlo et al. regarding our recently published Brief Report.1 The experiences they shared in the management of patients with chylous ascites on selpercatinib are an important contribution to the literature. As Provenzano et al. mentioned, nontraumatic chylous effusions are rare2 and current management strategies are primarily on the basis of data pertaining to traumatic and iatrogenic chylous effusions, which are more prevalent.3 In our cohort, chylous effusions were most prevalent among patients treated with the selective RET inhibitor, selpercatinib; however, they were also observed among patients treated with multikinase inhibitors with anti-RET activity, specifically cabozantinib, lenvatinib, and agerafenib. Full-Text PDF